Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Rating of “Buy” from Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned an average rating of “Buy” from the six research firms that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $11.20.

Several research analysts have recently issued reports on the stock. Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 9th. Leerink Partners restated an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a research report on Monday, September 9th. B. Riley assumed coverage on shares of Immunic in a report on Tuesday, August 27th. They set a “buy” rating and a $6.00 target price for the company. StockNews.com upgraded Immunic from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $28.00 price target on shares of Immunic in a research report on Tuesday, July 16th.

Immunic Stock Up 2.0 %

NASDAQ IMUX opened at $1.52 on Monday. The company has a 50-day simple moving average of $1.40 and a two-hundred day simple moving average of $1.31. Immunic has a 12-month low of $0.95 and a 12-month high of $1.92. The firm has a market cap of $136.92 million, a price-to-earnings ratio of -0.83 and a beta of 1.82.

Immunic (NASDAQ:IMUX) last issued its earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.02. During the same period in the previous year, the firm earned ($0.54) EPS. Equities analysts expect that Immunic will post -0.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunic

A number of institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in shares of Immunic during the 1st quarter worth approximately $25,000. Sierra Summit Advisors LLC purchased a new stake in Immunic in the fourth quarter worth $487,000. Ikarian Capital LLC grew its stake in Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after purchasing an additional 1,162,378 shares during the period. Gratus Capital LLC raised its holdings in Immunic by 15.1% in the fourth quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock worth $2,912,000 after purchasing an additional 254,999 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Immunic by 100.7% during the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after buying an additional 1,703,047 shares during the period. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.